PP
SGMO

PrairieView Partners’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

PrairieView Partners’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$0 Sell
35
-30
-46% -$18 ﹤0.01% 388
2025
Q1 		$0 Hold
65
– – ﹤0.01% 386
2024
Q4 		$0 Buy
+65
New +$119 ﹤0.01% 387
2021
Q4 		– Sell
-70
Closed -$1K – 437
2021
Q3 		$1K Buy
+70
New +$692 ﹤0.01% 361

Other funds holding SGMO

YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PrairieView Partners's SGMO Position: Q2 2025 in Review

PrairieView Partners reduced its SANGAMO THERAPEUTICS INC (SGMO) stake by 46% in Q2 2025, selling an estimated $18 and leaving 35 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #388.

PrairieView Partners first reported a position in SGMO in Q3 2021 and has held it in 4 quarters since. The position peaked at $1K in Q3 2021. 114 funds tracked by Wall St. Rank hold SGMO as of Q2 2025.

  • PrairieView Partners held 35 shares of SANGAMO THERAPEUTICS INC worth $0 as of Q2 2025.
  • PrairieView Partners sold 30 SANGAMO THERAPEUTICS INC shares in Q2 2025, an estimated $18.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of PrairieView Partners's portfolio in Q2 2025, its #388 holding.
  • PrairieView Partners first reported a position in SANGAMO THERAPEUTICS INC in Q3 2021 and has held it in 4 quarters since.
  • PrairieView Partners's SANGAMO THERAPEUTICS INC position peaked at $1K in Q3 2021.
  • 114 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2025.

Based on PrairieView Partners's 13F filing for Q2 2025, filed 25 Jul 2025.